The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. (Q40169126)
Jump to navigation
Jump to search
scientific article published on 19 February 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. |
scientific article published on 19 February 2007 |
Statements
1 reference
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. (English)
1 reference
Weir BA
1 reference
Minami Y
1 reference
Shimamura T
1 reference
Shah K
1 reference
LaFramboise T
1 reference
Glatt KA
1 reference
Liniker E
1 reference
Borgman CL
1 reference
Haringsma HJ
1 reference
Feng W
1 reference
Lowell AM
1 reference
Lee JC
1 reference
Wolf J
1 reference
Shapiro GI
1 reference
Wong KK
1 reference
Meyerson M
1 reference
Thomas RK
1 reference
19 February 2007
1 reference
5023-5027
1 reference
Identifiers
1 reference